See more : Entergy Texas, Inc. (ETI-P) Income Statement Analysis – Financial Results
Complete financial analysis of Venus Medtech (Hangzhou) Inc. (VMTHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Venus Medtech (Hangzhou) Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Senba Sensing Technology Co.,Ltd. (300701.SZ) Income Statement Analysis – Financial Results
- momo.com Inc. (8454.TW) Income Statement Analysis – Financial Results
- Doric Nimrod Air Two Limited (DNA2.L) Income Statement Analysis – Financial Results
- ATI Airtest Technologies Inc. (AATGF) Income Statement Analysis – Financial Results
- GlobeX Data Ltd. (SWIS.CN) Income Statement Analysis – Financial Results
Venus Medtech (Hangzhou) Inc. (VMTHF)
About Venus Medtech (Hangzhou) Inc.
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 491.37M | 406.46M | 415.86M | 276.05M | 233.27M |
| Cost of Revenue | 102.17M | 92.46M | 91.52M | 48.77M | 38.61M |
| Gross Profit | 389.21M | 314.00M | 324.34M | 227.28M | 194.67M |
| Gross Profit Ratio | 79.21% | 77.25% | 77.99% | 82.33% | 83.45% |
| Research & Development | 524.92M | 527.45M | 258.34M | 167.25M | 200.53M |
| General & Administrative | 153.79M | 192.18M | 128.59M | 104.06M | 197.61M |
| Selling & Marketing | 300.48M | 260.38M | 216.07M | 134.57M | 124.57M |
| SG&A | 454.26M | 452.56M | 344.65M | 238.64M | 322.18M |
| Other Expenses | -589.97M | -557.30M | -387.34M | -121.61M | 0.00 |
| Operating Expenses | 389.21M | 948.88M | 596.30M | 376.14M | 573.36M |
| Cost & Expenses | 1.08B | 1.04B | 687.82M | 424.91M | 611.96M |
| Interest Income | 34.46M | 34.65M | 49.48M | 34.67M | 2.85M |
| Interest Expense | 62.72M | 44.62M | 1.91M | 2.16M | 9.01M |
| Depreciation & Amortization | 124.79M | 112.35M | 51.62M | 37.71M | 20.24M |
| EBITDA | -547.84M | -999.37M | -324.03M | -145.97M | -307.81M |
| EBITDA Ratio | -111.49% | -240.47% | -137.04% | -72.28% | -131.95% |
| Operating Income | -589.97M | -1.09B | -621.53M | -237.25M | -328.04M |
| Operating Income Ratio | -120.07% | -268.11% | -149.46% | -85.94% | -140.63% |
| Total Other Income/Expenses | -145.37M | -521.46M | -105.60M | -7.24M | -53.50M |
| Income Before Tax | -735.34M | -1.16B | -377.56M | -185.84M | -381.54M |
| Income Before Tax Ratio | -149.65% | -284.49% | -90.79% | -67.32% | -163.56% |
| Income Tax Expense | -6.28M | -34.30M | -6.16M | -2.98M | 778.00K |
| Net Income | -703.75M | -1.06B | -373.64M | -181.99M | -380.72M |
| Net Income Ratio | -143.22% | -260.22% | -89.85% | -65.93% | -163.21% |
| EPS | -1.61 | -2.42 | -0.85 | -0.44 | -1.22 |
| EPS Diluted | -1.61 | -2.42 | -0.85 | -0.44 | -1.22 |
| Weighted Avg Shares Out | 437.90M | 437.90M | 438.58M | 409.27M | 311.04M |
| Weighted Avg Shares Out (Dil) | 437.90M | 437.90M | 438.58M | 409.27M | 311.04M |
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval
Source: https://incomestatements.info
Category: Stock Reports